metaEvidence - overview

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced hepatocellular cancer (mHCC)
mHCC - (neo)adjuvant (NA)
mHCC - 1st line (L1) 4
mHCC - 2nd line (L2) 2
lung cancer : non small cell (NSCLC) 5

immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus bevacizumab
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab plus lenvatinib
sintilimab based treatment
sintilimab

versus all
vs VEGF(R) inhibitor
vs lenvatinib
vs sorafenib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

button bars forest bayes pooled summary circles


			deaths (OS)
mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open